Skip to Content
MilliporeSigma

PZ0191

Crizotinib

≥98% (HPLC), c-Met (hepatocyte growth factor receptor) inhibitor, powder

Crizotinib

Synonym(s):

(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, PF 2341066, PF-02341066, PF02341066, Xalkori

Slide 1 of 1
Sign In to View Organizational & Contract Pricing

Select a Size

5 MG

$146.00

$146.00

Available to ship TODAYDetails

Request a Bulk Order
Ships Every 4 weeks

About This Item

Empirical Formula (Hill Notation):
C21H22Cl2FN5O
CAS Number:
877399-52-5
Molecular Weight:
450.34
MDL number:
MFCD12407409
UNSPSC Code:
12352200
PubChem Substance ID:
329823765
NACRES:
NA.77

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Crizotinib, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

color

white to tan

storage temp.

room temp

SMILES string

C[C@@H](Oc1cc(cnc1N)-c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl

InChI

1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

InChI key

KTEIFNKAUNYNJU-GFCCVEGCSA-N

Gene Information

human ... ALK(238), MET(4233)

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PZ0195PZ0242PZ0351
Crizotinib ≥98% (HPLC)

Sigma-Aldrich

PZ0191

Crizotinib

CYP3cide ≥98% (HPLC)

Sigma-Aldrich

PZ0195

CYP3cide

PF-06658607 ≥98% (HPLC)

Sigma-Aldrich

PZ0242

PF-06658607

PF-2545920 hydrochloride ≥97% (HPLC)

Sigma-Aldrich

PZ0351

PF-2545920 hydrochloride

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥97% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

room temp

storage temp.

room temp

storage temp.

room temp

storage temp.

room temp

color

white to tan

color

white to beige

color

white to beige

color

white to brown

Gene Information

human ... ALK(238), MET(4233)

Gene Information

-

Gene Information

-

Gene Information

-

Application

Crizotinib has been used:
  • to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis[1]
  • to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells[2]
  • to restore sensitivity to erlotinib[3]

Biochem/physiol Actions

ATP-competitive c-MET / ALK Inhibitor
Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). Crizotinib is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

signalword

Warning

Hazard Classifications

Aquatic Acute 1 - Eye Irrit. 2 - Muta. 2 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000489022
0000489022
0000360769
0000360769
0000187253

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shota Yamamoto et al.
Radiology, 272(2), 568-576 (2014-06-03)
To present a radiogenomic computed tomographic (CT) characterization of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) (ALK+). In this HIPAA-compliant institutional review board-approved retrospective study, CT studies, ALK status, and clinical-pathologic data in 172 patients with NSCLC from
Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
Greenfield E, et al.
eLife, 3, e04037-e04037 (2014)
PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells
Chen C, et al.
Experimental and Therapeutic Medicine, 15(5), 4543-4549 (2018)
Nicole R Infarinato et al.
Cancer discovery, 6(1), 96-107 (2015-11-12)
Neuroblastomas harboring activating point mutations in anaplastic lymphoma kinase (ALK) are differentially sensitive to the ALK inhibitor crizotinib, with certain mutations conferring intrinsic crizotinib resistance. To overcome this clinical obstacle, our goal was to identify inhibitors with improved potency that
Damini Chand et al.
Disease models & mechanisms, 6(2), 373-382 (2012-10-30)
Neuroblastoma is a childhood extracranial solid tumour that is associated with a number of genetic changes. Included in these genetic alterations are mutations in the kinase domain of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), which have been
View All Related Papers

Articles

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

1 Review This action will navigate to reviews.

Questions

Reviews

Active Filters

  1. 1 Ratings-Only Review

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service